Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Posterior brain damage and cognitive impairment in pediatric multiple sclerosis.
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
[Unified assessment of adverse events of multiple sclerosis disease modifying drugs.]
The analysis of correlation between IL-1B gene expression and genotyping in multiple sclerosis patients.
Speedy eye movements in multiple sclerosis: Association with performance on visual and nonvisual cognitive tests.
Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica.
Neurologic complications in patients with inflammatory bowel disease: Increasing relevance in the era of biologics.
Limb Apraxia in Multiple Sclerosis: Prevalence and Impact on Manual Dexterity and Activities of Daily Living.
Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk.
Pathophysiology of the brain extracellular matrix: a new target for remyelination.
Alemtuzumab 3-year data show durable effect on MS disability
The validity and reliability of the neurogenic bladder symptom score (NBSS).
Riluzole inhibits spontaneous Ca2+ signaling in neuroendocrine cells by activation of K+ channels and inhibition of Na+ channels.
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.
Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy.
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Impact of Depression, Fatigue and Disability on Quality of Life in Chinese Patients with Multiple Sclerosis.
Clinical analysis of the etiology of optic neuritis in patients at different ages in china.
Neurorehabilitation for other neurologic disorders.
Assessing upper limb function in multiple sclerosis.
Riluzole increases glutamate uptake by cultured C6 astroglial cells.
Venocentric Lesions: An MRI Marker of MS?
Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes.
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.
Pages
« first
‹ previous
…
197
198
199
200
201
202
203
204
205
…
next ›
last »